19 filings
6-K
PRQR
ProQR Therapeutics N.V
11 Dec 19
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
8:46am
6-K
PRQR
ProQR Therapeutics N.V
21 Nov 19
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
4:09pm
6-K
PRQR
ProQR Therapeutics N.V
12 Nov 19
PROQR THERAPEUTICS N.V. Index to Unaudited Condensed Consolidated Financial Statements
4:03pm
6-K
PRQR
ProQR Therapeutics N.V
17 Oct 19
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
4:26pm
6-K
PRQR
ProQR Therapeutics N.V
16 Oct 19
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
6:11am
6-K
ro1v0v4f c8l6
10 Oct 19
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
8:05am
6-K
on6168
9 Sep 19
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
4:30pm
6-K
z6sb3o
12 Aug 19
Current report (foreign)
4:04pm
6-K
mbm7 ik9z12ls79r071h
7 Aug 19
Current report (foreign)
7:55am
6-K
5qbe81t3bsf2
29 Jul 19
Current report (foreign)
4:03pm
6-K
3f4w5sbl24t0a 02so
21 May 19
Current report (foreign)
4:03pm
6-K
bqp1lxx2r99pvot597tw
8 May 19
Current report (foreign)
4:13pm
6-K
qom9jlw9msjis25bvlf
22 Apr 19
ProQR Announces Annual Meeting of Shareholders
12:00am
6-K
4utet 3lukhvg
15 Apr 19
ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
7:56am
6-K
c09dzc
26 Mar 19
ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
4:11pm
6-K
whmhwb6kz2i1o2rvo
11 Mar 19
ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
5:02pm
6-K
0uunr8 g5l4
27 Feb 19
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
8:27am
6-K
30ozq r0e5e3o341wfz
29 Jan 19
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
8:47am
6-K
00f37
7 Jan 19
ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
7:05am
- Prev
- 1
- Next